文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

评估 CAR-T 细胞在患者来源的胶质母细胞瘤模型中的作用。

evaluation of CAR-T cells in patient-derived glioblastoma models.

机构信息

Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON L8S 4L8, Canada.

Department of Surgery, McMaster University, Hamilton, ON L8S 4L8, Canada.

出版信息

STAR Protoc. 2021 Oct 29;2(4):100920. doi: 10.1016/j.xpro.2021.100920. eCollection 2021 Dec 17.

DOI:10.1016/j.xpro.2021.100920
PMID:34761232
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8567433/
Abstract

Advances in chimeric antigen receptor (CAR) T cell therapies have led to the modality dominating translational cancer research; however, a standardized protocol for evaluating such therapies is needed. This protocol details the preclinical evaluation of CAR-T cell therapies for glioblastoma (GBM), including target cell cytotoxicity and T cell proliferation, activation, and cytokine release assays. For complete details on the use and execution of this protocol, please refer to Vora et al. (2020).

摘要

嵌合抗原受体 (CAR) T 细胞疗法的进展使得该模式主导了癌症转化研究；然而，需要一种标准化的方案来评估这种疗法。本方案详细介绍了用于胶质母细胞瘤 (GBM) 的 CAR-T 细胞疗法的临床前评估，包括靶细胞细胞毒性和 T 细胞增殖、激活和细胞因子释放测定。有关该方案使用和实施的详细信息，请参见 Vora 等人（2020 年）。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a6f3/8567433/35cadd16d4d3/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a6f3/8567433/e8c44941f596/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a6f3/8567433/cbf8af2f0700/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a6f3/8567433/35cadd16d4d3/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a6f3/8567433/e8c44941f596/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a6f3/8567433/cbf8af2f0700/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a6f3/8567433/35cadd16d4d3/gr2.jpg

相似文献

[1]
evaluation of CAR-T cells in patient-derived glioblastoma models.

STAR Protoc. 2021-12-17

[2]
Development of Antigen-specific Chimeric Antigen Receptor KHYG-1 Cells for Glioblastoma.

Anticancer Res. 2021-4

[3]
Preclinical Testing of CAR T Cells in a Patient-Derived Xenograft Model of Glioblastoma.

STAR Protoc. 2020-12-18

[4]
Intracranial CAR-T cell delivery in glioblastoma patients.

Trends Cancer. 2024-6

[5]
Current progress in chimeric antigen receptor T cell therapy for glioblastoma multiforme.

Cancer Med. 2021-8

[6]
Next-generation CAR T cell therapies for glioblastoma.

Sci Transl Med. 2024-8-28

[7]
Protocol for preclinical evaluation of locoregionally delivered CAR T cells in patient-derived xenograft models of brain tumors.

STAR Protoc. 2024-6-21

[8]
The update of chimeric antigen receptor-T cells therapy in glioblastoma.

J Chin Med Assoc. 2020-5

[9]
Enhancing Glioblastoma Immunotherapy with Integrated Chimeric Antigen Receptor T Cells through the Re-Education of Tumor-Associated Microglia and Macrophages.

ACS Nano. 2024-4-30

[10]
CAR T-cell therapy for glioblastoma: ready for the next round of clinical testing?

Expert Rev Anticancer Ther. 2018-3-16

引用本文的文献

[1]
Advances in Gene Therapy with Oncolytic Viruses and CAR-T Cells and Therapy-Related Groups.

Curr Issues Mol Biol. 2025-4-10

[2]
Bioluminescent Imaging of Patient-Derived Brain Tumors in Live Mice.

Methods Mol Biol. 2025

[3]
Pre-Clinical Models for CAR T-Cell Therapy for Glioma.

Cells. 2024-9-4

[4]
Current approaches in glioblastoma multiforme immunotherapy.

Clin Transl Oncol. 2024-7

[5]
ICOS and OX40 tandem co-stimulation enhances CAR T-cell cytotoxicity and promotes T-cell persistence phenotype.

Front Oncol. 2023-8-18

[6]
Assessment of CAR-T Cell-Mediated Cytotoxicity in 3D Microfluidic Cancer Co-Culture Models for Combination Therapy.

IEEE Open J Eng Med Biol. 2022-5-27

本文引用的文献

[1]
Comparative analysis of assays to measure CAR T-cell-mediated cytotoxicity.

Nat Protoc. 2021-3

[2]
A Patient-Derived Xenograft Model of Glioblastoma.

STAR Protoc. 2020-12-18

[3]
Preclinical Testing of CAR T Cells in a Patient-Derived Xenograft Model of Glioblastoma.

STAR Protoc. 2020-12-18

[4]
The Rational Development of CD133-Targeting Immunotherapies for Glioblastoma.

Cell Stem Cell. 2020-6-4

[5]
Luciferase mRNA Transfection of Antigen Presenting Cells Permits Sensitive Nonradioactive Measurement of Cellular and Humoral Cytotoxicity.

J Immunol Res. 2016-1-5

[6]
Measuring cytotoxicity by bioluminescence imaging outperforms the standard chromium-51 release assay.

PLoS One. 2014-2-19

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索